Orphanet Journal of Rare Diseases | Public Preferences for Public Funding Decisions of Rare Disease Drugs in Australia

Recommend:

This study, using the Discrete Choice Experiment (DCE) method, reveals the key factors that influence public preferences when deciding on funding for rare disease drugs, including survival extension, credibility of clinical evidence, and improvement in patients' quality of life, providing valuable insights for policymakers.

 

Literature Overview

This article, titled 'Using a discrete choice experiment to explore societal preferences for valuing new drugs for rare diseases', published in the Orphanet Journal of Rare Diseases, reviews and summarizes public preferences in Australia regarding the funding of new drugs. The study finds that the public generally prefers drugs that extend survival, are supported by stronger clinical evidence, and improve patients' daily activities. Using mixed logit regression and latent class models, the study reveals heterogeneity in public preferences, identifying three distinct preference groups, with more than half of the respondents prioritizing survival extension.

Background Knowledge

Rare diseases refer to conditions with very few patients, yet collectively they affect approximately 6-8% of the global population. Due to the small number of patients, clinical trials are difficult to conduct, and drug development and evaluation face many challenges. Although health technology assessment (HTA) frameworks exist to evaluate the value of new drugs, traditional cost-effectiveness analyses are often unsuitable in the field of rare diseases due to high treatment costs and insufficient evidence of efficacy. This study, based on a representative Australian population sample (n=1099), investigates public preferences regarding drug funding using the DCE method, focusing on attributes such as uncertainty in clinical evidence, unmet therapeutic needs, clinical benefit size, quality of life improvements, and total government costs. The study also incorporates focus groups and literature reviews to ensure the scientific validity and representativeness of the selected attributes.

 

A practical tool for quickly mapping DNA or RNA sequences to the genome, suitable for genomics research.

Learn More

 

Research Methods and Design

The study employed a Discrete Choice Experiment (DCE) design, collecting public preferences through an online survey in hypothetical scenarios. Six key attributes were identified: uncertainty in clinical evidence, unmet therapeutic need, impact on survival and quality of life, and total annual government expenditure. Data were analyzed using mixed logit regression and latent class models to assess preference heterogeneity and estimate marginal willingness to pay (WTP) for each attribute.

Key Findings and Insights

• The general public prefers drugs that extend survival, have strong clinical evidence, and improve quality of life.
• About 58% of respondents (Class 3) strongly support drugs that extend survival, followed by 21% (Class 2) who prioritize credibility of clinical evidence, and another 21% (Class 1) who favor drugs with high government cost.
• Improvements in patients' daily activities are highly valued, while the public is generally insensitive to the level of unmet therapeutic need.
• The public is willing to pay approximately AUD 259,000 for a drug that extends survival by 5 years, AUD 104,000 for a 1-year extension, and AUD 185,000 for improved credibility of clinical evidence.
• Significant heterogeneity in public preferences was observed, with different groups valuing drug attributes differently, suggesting that policy decisions should consider diverse societal values.

Implications and Future Directions

This study provides empirical evidence for rare disease drug funding policies based on public preferences, emphasizing the importance of prioritizing key attributes such as survival extension and evidence credibility under resource constraints. Future research could further refine preferences across different social groups, explore relationships with variables such as personal experience and education level, and incorporate real-world data to enhance the external validity of the findings.

 

Evaluates the pathogenicity of genetic variants, providing a reference for variant analysis, suitable for genetic and personalized medicine research.

Learn More

 

Conclusion

This study systematically assessed Australian public preferences regarding funding decisions for rare disease drugs using a Discrete Choice Experiment (DCE). It was found that the public generally supports drugs that extend survival, improve quality of life, and have stronger clinical evidence. However, there is significant heterogeneity in preferences, with different groups valuing drug attributes differently, indicating that policy decisions should consider diverse societal values. Although the study sample is representative, its geographical limitations should be acknowledged. Future research could extend to other countries and explore how public education and personal experiences influence preference structures. Additionally, the study highlights that ensuring equity while improving access to rare disease drugs remains a key challenge for policymakers. This study provides empirical support for optimizing the evaluation framework of rare disease drugs, contributing to more reasonable societal value judgments.

 

Constanza Vargas, Stephen Goodall, Deborah J Street, Manuel Espinoza, and Richard De Abreu Lourenço. Using a discrete choice experiment to explore societal preferences for valuing new drugs for rare diseases. Orphanet Journal of Rare Diseases.